Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A new statin: a new standard.

A G Olsson1

  • 1Clinical Research Center, University Hospital, Linköping, Sweden. andol@kfc.liu.se

Clinical Cardiology
|August 15, 2001
PubMed
Summary
This summary is machine-generated.

New statin rosuvastatin significantly lowers low-density lipoprotein cholesterol (LDL-C), reducing coronary heart disease (CHD) risk. It offers greater LDL-C reduction than other statins, benefiting more patients with high cholesterol.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Can LDL cholesterol be too low? Possible risks of extremely low levels.

Journal of internal medicine·2017
Same author

Macrophage erythrophagocytosis and iron exocytosis.

Redox report : communications in free radical research·2016
Same author

HDL and LDL as therapeutic targets for cardiovascular disease prevention: the possible role of niacin.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2010
Same author

Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial.

Journal of internal medicine·2010
Same author

Well-being in patients with amyotrophic lateral sclerosis and their next of kin over time.

Acta neurologica Scandinavica·2009
Same author

Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.

International journal of clinical practice·2009

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Lipid Metabolism

Background:

  • Low-density lipoprotein cholesterol (LDL-C) reduction is key for preventing coronary heart disease (CHD).
  • Current statins are first-line therapy but often fail to achieve target LDL-C levels in many patients.
  • A need exists for more effective LDL-C-lowering therapies.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of rosuvastatin, a novel, highly efficacious statin.
  • To compare rosuvastatin's lipid-lowering effects with existing statins.

Main Methods:

  • Dose-ranging studies in hypercholesterolemic patients compared rosuvastatin to placebo.
  • Phase III trials assessed rosuvastatin's efficacy against atorvastatin, pravastatin, and simvastatin.

Related Experiment Videos

Main Results:

  • Rosuvastatin demonstrated significant, dose-dependent LDL-C reductions (34%–65%).
  • It was well tolerated across all studied doses.
  • Rosuvastatin showed greater efficacy than atorvastatin, pravastatin, and simvastatin in improving lipid profiles.

Conclusions:

  • Rosuvastatin is a highly effective and well-tolerated statin for lowering LDL-C.
  • This novel agent shows promise for treating dyslipidemias and extending benefits of aggressive LDL-C reduction.